Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

AC Immune S.A. (NQ: ACIU )

8.370 USD +0.240 (+2.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 510,190
Open 8.230
Bid (Size) 8.250 (50)
Ask (Size) 8.500 (3)
Prev. Close 8.130
Today's Range 8.160 - 8.640
52wk Range 4.420 - 13.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
4 Top Health Care Stocks To Watch This Week
Tags Market News
From StockMarket.com
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
From GlobeNewswire News Releases

Performance

YTD
+57.33%
+57.33%
1 Month
+30.99%
+30.99%
3 Month
+7.86%
+7.86%
6 Month
+51.91%
+51.91%
1 Year
+23.45%
+23.45%

More News

Read More
AC Immune to Highlight First-in-Class Alzheimer’s Disease Vaccine Programs at Upcoming Investor Conferences
From GlobeNewswire News Releases
AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update
From GlobeNewswire News Releases
OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
From GlobeNewswire News Releases
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
From GlobeNewswire News Releases
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease
From GlobeNewswire News Releases
Monday Sector Leaders: Shipping, Drugs
Tags Stocks
From Market News Video
Thinking about buying stock in AC Immune, Ashford Hospitality Trust, Sorrento Therapeutics, Jaguar Health, or Exela Technologies?
From PR Newswire
AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile
Tags Phase 2 Trial Alzheimer's disease Biotech
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.